APA (7th ed.) Citation

Ciracì, P., Germani, M., Pietrantonio, F., Lonardi, S., Busico, A., Chiaramonte, A., . . . Cremolini, C. (2025). 4O Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial. Annals of Oncology, 36, S4. https://doi.org/10.1016/j.annonc.2025.05.016

Chicago Style (17th ed.) Citation

Ciracì, P., et al. "4O Liquid Biopsy-guided Selection for Anti-EGFR Re-treatment in RAS/BRAF Wild-type (wt) Chemorefractory Metastatic Colorectal Cancer Patients (mCRC Pts): Results from the Phase II Randomized PARERE Trial." Annals of Oncology 36 (2025): S4. https://doi.org/10.1016/j.annonc.2025.05.016.

MLA (9th ed.) Citation

Ciracì, P., et al. "4O Liquid Biopsy-guided Selection for Anti-EGFR Re-treatment in RAS/BRAF Wild-type (wt) Chemorefractory Metastatic Colorectal Cancer Patients (mCRC Pts): Results from the Phase II Randomized PARERE Trial." Annals of Oncology, vol. 36, 2025, p. S4, https://doi.org/10.1016/j.annonc.2025.05.016.